Obsidian Therapeutics
Aspires to extend adoptive immunotherapy.
Launch date
Employees
Market cap
-
Enterprise valuation
€584—875m (Dealroom.co estimates Apr 2024.)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$49.5m | Series A | ||
$115m | Series B | ||
* | $161m | Series C | |
Total Funding | €295m |
Related Content
Recent News about Obsidian Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.